TRACON Pharmaceuticals , a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, today announced the initiation of a two cohort clinical trial sponsored by the National Cancer Institute , containing a Phase 2 portion evaluating the combination of TRC102 and AlimtaA in patients with mesothelioma and a Phase 1b portion evaluating the combination of TRC102, Alimta and cisplatin in patients with solid tumors.
